Search

Your search keyword '"Touitou, Irit"' showing total 12 results
Start Over Author "Touitou, Irit"
12 results on '"Touitou, Irit"'

1. COVID-19 patient experiences in prehospital pathways: a processual approach using life-events calendar method and state sequence analysis shows detrimental delays

Author

Patrick Peretti-Watel, Sébastien Cortaredona, Christian Pradier, Gaetan Gentile, Stéphanie Gentile, Philippe Brouqui, Michel Carles, Romain Lutaud, Lea Delorme, Juliette Mirouse, Manon Borg, Lucie Cattaneo, Didier Thery, Touitou Irit, and Sophie Tardieu

Subjects
Medicine (General), R5-920
Abstract

Objectives To our best knowledge, no study in France has comprehensively investigated the prehospital history of patients admitted for severe cases of COVID-19. ‘Patients’ voice is an excellent means to capture data on primary care pathways.We aimed to identify clusters of COVID-19 hospitalised patients with similar prehospital symptom sequences, and to test whether these clusters were associated with a higher risk of poor clinical outcomes.Design Cross-sectional online survey using life-event calendars.Setting All patients hospitalised for COVID-19 between September 2020 and May 2021 in the Infectious Disease Departments in Nice and in Marseilles in France.Participants 312 patients responded to the survey.Main outcome measures From the day of symptom onset to the day of hospitalisation, we defined a symptom sequence as the time-ordered vector of the successive symptom grades (grade 1, grade 2, grade 3). State sequence analysis with optimal matching was used to identify clusters of patients with similar symptom sequences. Multivariate logistic regressions were performed to test whether these clusters were associated with admission to intensive care unit (ICU) and COVID-19 sequelae after hospitalisation.Results Three clusters of symptom sequences were identified among 312 complete prehospital pathways. A specific group of patients (29%) experienced extended symptoms of severe COVID-19, persisting for an average duration of 7.5 days before hospitalisation. This group had a significantly higher probability of being admitted to ICU (adjusted OR 2.01). They were less likely to know a loved one who was a healthcare worker, and more likely to have a lower level of education. Similarly, this group of patients, who were more likely to have previously visited the emergency room without exhibiting severe symptoms at that time, may have been inclined to postpone reassessment when their health worsened.Their relatives played a decisive role in their hospitalisation.Conclusion and relevance This study highlights the negative impact of delayed hospitalisation on the health outcomes of French patients with severe COVID-19 symptoms during the first wave and underscores the influence of socioeconomic factors, such as lower education levels and limited connections to the medical field, on patients’ experiences.

Published
2024
Full Text
View/download PDF

3. Facilitating the access to HIV testing at lower costs: "To the laboratory without prescription" (ALSO), a pilot intervention to expand HIV testing through medical laboratories in France.

Author

Champenois, Karen, Sawras, Victoire, Ngoh, Pamela, Bouvet de la Maisonneuve, Philippe, Valbousquet, Julie, Annequin, Margot, Gatseva, Yoana, Michels, David, Lydié, Nathalie, Maguet, Charlotte, Aïna, Elodie, Le Hô, Erwann, Plenel, Eve, Touitou, Irit, Deuffic-Burban, Sylvie, Lert, France, and Pugliese, Pascal

Subjects
DIAGNOSIS of HIV infections, HETEROSEXUAL men, BUSINESS hours, CITIES & towns, HEALTH insurance, MEDICAL laboratories
Abstract

Background: A pilot HIV testing programme, Au Labo sans Ordo (ALSO; "to the laboratory without prescription") was implemented in two French Fast-Track Cities Initiative areas from 07/2019 to 12/2020. ALSO aimed to remove barriers to HIV testing by providing free testing with widespread access through all laboratories, extended opening hours, and no prescription requirements. Objectives: Assessing the ALSO programme in terms of testing activity, user characteristics, and costs, compared to other HIV testing offers. Methods: Laboratories and STI clinics reported the monthly numbers of tests performed and positive tests. Two short surveys were carried out 12 months apart in people who sought HIV testing. In each offer, the mean costs of HIV testing have been estimated according to negative or positive results using a microcosting approach. Results: During the study period, 214/264 laboratories reported performing 38,941 ALSO tests that accounted for 7.2% of laboratory HIV testing activity. Positivity rates of ALSO and prescribed tests were similar (2.2/1000) but lower than that in STI clinics (6.0/1000). Heterosexual men, and individuals with multiple sexual partners, poor health insurance and few visits to GPs were more likely to use the ALSO offer than tests upon prescription. Compared to ALSO, STI clinic users were younger, more exposed to HIV and with a less favourable socio-economic situation. ALSO had low costs: €13 for a negative test, €163 for a positive test and €5,388 to identify an HIV-positive person (versus €9,068 in STI clinics and €20,126 with prescribed tests). Conclusion: ALSO has attracted users less likely to visit STI clinics or to seek a prescribed test, particularly heterosexual men. Activities, user profiles and costs suggested the complementarity of the HIV testing offers and the relevance of making them coexist. French health authorities have decided to maintain and expand this programme to complement existing HIV testing offers. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])*

Author

Carvelli, Julien, Meziani, Ferhat, Dellamonica, Jean, Cordier, Pierre-Yves, Allardet-Servent, Jerome, Fraisse, Megan, Velly, Lionel, Barbar, Saber Davide, Lehingue, Samuel, Guervilly, Christophe, Desgrouas, Maxime, Camou, Fabrice, Piperoglou, Christelle, Vely, Frederic, Demaria, Olivier, Karakunnel, Joyson, Fares, Joanna, Batista, Luciana, Rotolo, Federico, Viotti, Julien, Boyer-Chammard, Agnes, Lacombe, Karine, Le Dault, Erwan, Carles, Michel, Schleinitz, Nicolas, Vivier, Eric, Schleinitz, Nicolas, Carvelli, Julien, Gainnier, Marc, Bourenne, Jérémy, Bichon, Amandine, Le Saux, Audrey, Bouzana, Fouad, Tilmont, Antoine, Cauchois, Emi, Coularet, Charlotte, Bruder, Nicolas, Velly, Lionel, Ebbo, Mikael, Veit, Véronique, Jean, Estelle, Simeone, Pierre, Blasco, Valéry, Vely, Frédéric, Piperoglou, Christelle, Coutard, Bruno, Pastorino, Boris, Villaroel, Maria Saba, Garrido-Pradalie, Emilie, Amichi, Kahéna, Larosa, Aurélie, Blondelon, Aurélie, Inal, Imane, Amichi, Kahéna, Dhorne, Jean, Durieux, Frédérique, Brunet, Julie, Cohen, Anita, Deluca, Bénédicte, Malkoun, Richard, Dellamonica, Jean, Buscot, Matthieu, Saccheri, Clément, Carles, Michel, Demonchy, Elisa, Cua, Eric, Chirio, David, Courjon, Johan, Risso, Karine, Rigault, Marie-Christine, Gazoppi, Loïc, Salas, Virginie, Bouskila, Nadège, Touitou, Irit, Breaud, Sophie, Boughdiri, Nihed, Marrane, Guillaume, Meziani, Ferhat, Merdji, Hamid, Helms, Julie, Monier, Alexandra, Demiselle, Julien, Jandeaux, Louise-Marie, Studer, Antoine, Allam, Hayat, Thiebaut, Léonie, Hutt-Clauss, Anne, Le Dault, Erwan, Cordier, Pierre-Yves, Savini, Hélène, Clerc, Axelle, Spadoni, Sophie, Javelle, Emilie, Clerc, Axelle, Chouaki-Benmansour, Nassima, Le Garlantezec, Patrick, Le Tohic, Sarah, Allardet-Servent, Jérôme, Benarous, Lucas, Madjarian, Corinne, Aouadenne-Mesbah, Assia, Rognon, Amélie, Fraisse, Megan, Plantefeve, Gaétan, Benrezzak, Nasro, Dubief, Emeline, Chauvel, Olivia, Jamet, Charlotte, Davide Barbar, Saber, Ambert, Audrey, Lloret, Sophie, Elotmani, Loubna, Dubois, Grégory, Meyrieux, Séverine, Barthelemi, Laurie, Lehingue, Samuel, Poulet, Antoine, Bezirganyan, Kristina, Asselate, Belkacem, Provitolo, Vincent, Lacombe, Karine, Bollens, Diane, Letaillandier, Cyrielle, Tran, Christian, Sebire, Manuela, Lamarque, Julie, Deguenel-Nguyen, Anne, Desgrouas, Maxime, Jacquier, Sophie, Muller, Grégoire, Bretagnol, Anne, Mathonnet, Armelle, Benzekri, Dalila, Barbier, François, Mai-Anh, Nay, Runge, Isabelle, Kamel, Toufik, Muller, Lucie, Tellec, Sophie, Guervilly, Christophe, Papazian, Laurent, Forel, Jean-Marie, Sanz, Céline, Pinglis, Camille, Valera, Sabine, Colombini, Nathalie, Camou, Fabrice, Mourissoux, Gaelle, Guisset, Olivier, Issa, Nahéma, Pedenon-Peyrichout, Delphine, Delaune, Jean, Langlade, Claire, Pedeboscq, Stéphane, Lescure, Xavier, Isernia, Valentina, Bachelard, Antoine, Fleurot, Odile, Le Gac, Sylvie, Da Conceicao, Olivia, Julia, Zelie, Chalal, Lynda, Oualit, Lynda, Kramer, Laura, Le Grand, Jennifer, Poissy, Julien, Nseir, Saadalla, Mariller, Laure, Delcoutre, Claire, Brice, Sylvie, Lelievre, Jean-Daniel, Gallien, Sébastien, Cotellon, Christine, Vindrios, William, Melica, Giovanna, Natella, Pierre-André, Bourhis, Marion, Thiemele, Alaki, De Nailly, Delphine Lefebvre, Malvy, Denis, Desclaux, Arnaud, Ducours, Mailys, Perreau, Pauline, Boyer, Alexandre, Clouzeau, Benjamin, Bui, Hoang-Nam, Bourgoin, Nicolas, Kabala, Anna, Ghezzoul, Bellabes, Servant, Vincent, and Djabarouti, Sarah

Published
2022
Full Text
View/download PDF

5. Accurate Detection of SARS-CoV-2 by Next-Generation Sequencing in Low Viral Load Specimens

Author

Ilié, Marius, primary, Benzaquen, Jonathan, additional, Hofman, Véronique, additional, Long-Mira, Elodie, additional, Lassalle, Sandra, additional, Boutros, Jacques, additional, Bontoux, Christophe, additional, Lespinet-Fabre, Virginie, additional, Bordone, Olivier, additional, Tanga, Virginie, additional, Allegra, Maryline, additional, Salah, Myriam, additional, Fayada, Julien, additional, Leroy, Sylvie, additional, Vassallo, Matteo, additional, Touitou, Irit, additional, Courjon, Johan, additional, Contenti, Julie, additional, Carles, Michel, additional, Marquette, Charles-Hugo, additional, and Hofman, Paul, additional

Published
2023
Full Text
View/download PDF

6. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

Author

Legros, Laurence, Nicolini, Franck E., Etienne, Gabriel, Rousselot, Philippe, Rea, Delphine, Giraudier, Stéphane, Guerci‐Bresler, Agnès, Huguet, Françoise, Gardembas, Martine, Escoffre, Martine, Ianotto, Jean‐Christophe, Noël, Marie‐Pierre, Varet, Bruno R., Pagliardini, Thomas, Touitou, Irit, Morisset, Stéphane, and Mahon, Francois‐Xavier

Published
2017
Full Text
View/download PDF

7. Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Author

Legros, Laurence, Slama, Bohrane, Karsenti, Jean-Michel, Vey, Norbert, Natarajan-Amé, Shanti, Watel, Eric, Richard, Bruno, Bouabdallah, Krimo, Mannone, Lionel, Benchetrit, Maxime, Touitou, Irit, Huault, Sébastien, Durivault, Jérome, Ambroseti, Damien, Hueber, Anne-Odile, Fenaux, Pierre, Dreyfus, Francois, and on behalf the Groupe Francophone des Myélodysplasies (GFM)

Published
2012
Full Text
View/download PDF

8. Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study

Author

Legros, Laurence, Huguet, Francoise, Cony-Makhoul, Pascale, Touitou, Irit, Nicolini, Franck E., Rea, Delphine, Berger, Marc G., Uzunov, Madalina, Roy, Lydia, Escoffre Barbe, Martine, Guerci Bresler, Agnes, Etienne, Gabriel, Daguenet, Elisabeth, Penot, Amelie, Gardembas Pain, Martine, Ame, Shanti, Jourdan, Eric, Johnson-Ansah, Hyacinthe A., Coiteux, Valerie, Machet, Antoine, Lippert, Eric, Vekoff, Anne, Karsenti, Jean Michel, Morisset, Stéphane, and Mahon, Francois

Published
2023
Full Text
View/download PDF

9. Profiles of the ALSO program users, a a free hiv testing supply in walk-in medical labs in france

Author

Champenois, Karen, Annequin, Margot, Ngoh, Paméla, Touitou, Irit, Lert, France, Bouvet de la Maisonneuve, Philippe, Valbousquet, Julie, Le Hô, Erwan, Lydie, Nathalie, Plenel, Ève, Pugliese, Pascal, Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Vers Paris sans sida [Paris], Corevih Paca Est, Centre Hospitalier Universitaire de Nice (CHU Nice), Objectif sida zéro [Nice], Santé publique France - French National Public Health Agency [Saint-Maurice, France], Groupe ALSO ((« Au labo sans ordo ») : Laurence Dauffy, Laurence Dumondin et les équipes de l’Assurance maladie de Paris, Gwenaelle Tasset et les équipes de l’Assurance maladie des Alpes-Maritimes, Anne-Claire Haye, Gérard Ughetto et les équipes du Service médical de l’Assurance maladie, Florence Orsini, Said Oumeddour et la sous-direction de prévention et promotion de la santé de l’Assurance maladie, Jean-Claude Azoulay et l’URPS Biologie Île-de-France (IDF), Boris Loquet, Jean-Marc Dubertrand et l’URPS Biologie Paca, les présidents et présidentes, ainsi que les techniciens et techniciennes d’études cliniques des Corevih Paca-Est, IDF Sud, IDF Nord, IDF Centre et IDF Ouest, Christophe Caissotti (Corevih Paca-Est), Frédéric Goyet, Corinne Chouraqui (Agence régionale de santé Île-de-France), Anne Souyris (Ville de Paris)., and Annequin, Margot

Subjects
CeGIDD, Dépistage, Public STI clinic, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Testing, HIV, VIH, Medical laboratory, Laboratoire de biologie médicale, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

Introduction – Since July 1st, 2019, the “Au labo sans ordo” (ALSO) program offers a free HIV testing solution, without prescription, in any walk-in medical laboratory in Paris and the Alpes-Maritimes. This article describes the ALSO program users’ profile and compares their characteristics to those of the persons who get tested for HIV in labs with a prescription or in public STI clinics.Methods – A cross-sectional survey was conducted on the week of November 18-23, 2019 in 240 medicallaboratories and 11 public STI clinics in both regions. An anonymous self-administered questionnaire wasproposed to every adult who got tested for HIV. Two logistic regression models were used to compare ALSO users to (1) prescription test users and (2) STI clinics clients.Results – 3,144 questionnaires were analyzed (295 ALSO users, 2,138 prescriptions test users and 711 STI clinics clients). Compared to people with a prescribed test, ALSO attracted more heterosexual men (42% vs 28%), better established socially but quite far from care (32% vs 21% see a doctor ≤ once a year), with multiple sexual partners (60% vs 49%). Public STI clinics attracted a younger population (42% vs 21%, Introduction – Depuis le 1er juillet 2019, le programme « Au labo sans ordo » (ALSO) offre, à Paris et dans les Alpes-Maritimes, un dépistage du VIH sans ordonnance et sans frais dans tous les laboratoires de biologie médicale de ville. Cet article décrit les usagers du programme ALSO et compare leurs caractéristiques à celles des personnes qui ont recours au dépistage du VIH en laboratoire sur prescription médicale ou en CeGIDD.Méthodes – Une étude transversale a été menée la semaine du 18 au 23 novembre 2019 dans 240 laboratoires et 11 CeGIDD, dans les deux départements. Un autoquestionnaire anonyme était proposé par le personnel d’accueil aux personnes majeures qui réalisaient un test VIH. Deux modèles de régression logistique ont permis de comparer les usagers ALSO aux personnes avec (1) un test prescrit ; (2) un dépistage en CeGIDD.Résultats – L’analyse portait sur 3 144 questionnaires (295 usagers ALSO, 2 138 personnes avec un testprescrit et 711 usagers des CeGIDD). Comparativement aux personnes avec un test prescrit, ALSO attiraitdavantage d’hommes hétérosexuels (42% vs 28%), bien insérés socialement mais assez éloignés du soin(32% vs 21% consultaient ≤1 fois/an), multipartenaires (60% vs 49%). Les CeGIDD touchaient une population plus jeune (42% vs 21%

Published
2020

10. Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level

Author

Legros, Laurence, Slama, Bohrane, Karsenti, Jean-Michel, Vey, Norbert, Natarajan-Amé, Shanti, Watel, Eric, Richard, Bruno, Bouabdallah, Krimo, Mannone, Lionel, Benchetrit, Maxime, Touitou, Irit, Huault, Sébastien, Durivault, Jérome, Ambroseti, Damien, Hueber, Anne-Odile, Fenaux, Pierre, Dreyfus, Francois, Renseigné, Non, Institut de signalisation, biologie du développement et cancer (ISBDC), Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA), Hematology (IPC-Marseille), Laboratoire d'Informatique de l'Université du Mans (LIUM), Le Mans Université (UM), Institute of Developmental Biology and Cancer (IBDC), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie, and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP]

Subjects
Male, Vascular Endothelial Growth Factor A, medicine.medical_specialty, Bevacizumab, Angiogenesis, Angiogenesis Inhibitors, Bone Marrow Cells, Antibodies, Monoclonal, Humanized, Gastroenterology, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Bone Marrow, Internal medicine, Medicine, Humans, [SDV.BDD]Life Sciences [q-bio]/Development Biology, 030304 developmental biology, Aged, Aged, 80 and over, 0303 health sciences, Hematology, business.industry, Myelodysplastic syndromes, General Medicine, Middle Aged, medicine.disease, 3. Good health, Surgery, Vascular endothelial growth factor, medicine.anatomical_structure, Treatment Outcome, Tolerability, chemistry, 030220 oncology & carcinogenesis, Myelodysplastic Syndromes, Monoclonal, Female, Bone marrow, business, medicine.drug
Abstract

International audience; Myelodysplastic syndromes (MDS) are associated with increased bone marrow vascularity and increased levels of various angiogenic factors including Vascular Endothelial Growth Factor (VEGF) which is implicated in the proliferation and survival of leukemic cells. Before the approval of hypomethylating agents in this indication, the GFM conducted a multicenter phase II trial testing the efficacy and tolerance of bevacizumab, a humanized monoclonal antibody against VEGF, in MDS with excess of marrow blasts and its impact on bone marrow angiogenesis. Twenty-one patients were enrolled (16 males and five females) with a median age of 70 years and 19 were evaluable for haematological response after treatment (5 mg/kg IV every 2 weeks for 12 weeks). WHO diagnosis at baseline was RAEB-1 (38%) and RAEB-2 (62%). Treatment was well tolerated and was associated with significant decrease of VEGF plasma level [median (low quartile-high quartile)] from 65.5 pg/ml [LQ (low-quartile)-HQ (high quartile), 35.3-87.3 to 30.4 pg/ml (LQ-HQ, 22.5-34.0 pg/ml)] (p

Published
2011
Full Text
View/download PDF

11. Treatment of MDS with Excess Blasts by Bevacizumab Is Well Tolerated and Is Associated with a Decrease of VEGF Plasma Level.

Author

Legros, Laurence, primary, Slama, Boranne, additional, Karsenti, Jean-Michel, additional, Vey, Norbert, additional, Natarajan-Ame, Shanti, additional, Watel, Eric, additional, Richard, Bruno, additional, Bouabdallah, Krimo, additional, Mannone, Lionnel, additional, Touitou, Irit, additional, Huault, Sebastien, additional, Durivault, Jerome, additional, Hueber, Anne-Odile, additional, Michiels, Jean-Francois, additional, Fenaux, Pierre, additional, and Dreyfus, Francois, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results